Acambis lands $425M smallpox vaccine contract

The U.K.'s Acambis has won a $425 million contract to supply the CDC with its smallpox vaccine for 10 years. Acambis will establish a U.S.-based manufacturing capability for ACAM2000 and deliver a minimum of nine million doses per year of the drug. "The net proceeds will enable us to invest in manufacturing facilities for the U.S. contract, progress our vaccine for hospital-acquired C.difficile infections and further our program of new vaccines against influenza, genital herpes and other significant unmet medical needs," Acambis head Ian Garland told ShareCast.

- see the Acambis release
- read this report from ShareCast

Related Articles:
Sanofi buys into Acambis' West Nile vaccine program
Acambis' universal vaccine begins human clinical trials
Acambis shares plunge after U.S. nixes contract
Acambis completes vaccine BLA
Acambis researching single-shot solution to flu

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."